Work

Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

Year: 2020

Type: editorial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.19.03318

Authors: Eileen M. O’Reilly, Cristina Ferrone

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Massachusetts General Hospital

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W3009658764

Cites: 22

Cited by: 30

Related to: 10